{"filing":{"accession_number":"0001493152-26-039375","cik":"0001712762","ticker":"BIAFW","company_name":"bioAffinity Technologies, Inc.","form":"8-K","filing_date":"2026-08-20","report_date":"2026-08-20","primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1712762/000149315226039375/form8-k.htm"},"events":[{"id":28738,"run_id":26300,"accession_number":"0001493152-26-039375","anchor_item_number":null,"event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.85,"summary":"The filing discloses a 1-for-15 reverse stock split of bioAffinity Technologies' common stock, approved by stockholders at the April 30, 2026 annual meeting and effectuated via Certificate of Amendment filed August 20, 2026. The reverse split is a governance/capital structure event intended to bring the company into compliance with Nasdaq's minimum bid price requirement. While not a named governance category (exec appointment/departure, auditor change, shareholder vote results), this is clearly a material governance matter affecting all shareholders' holdings and the company's continued listing compliance.","company_name":"bioAffinity Technologies, Inc.","ticker":"BIAFW","filing_date":"2026-08-20","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":30780,"accession_number":"0001493152-26-039375","item_number":null,"item_title":null,"event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The filing discloses a 1-for-15 reverse stock split of bioAffinity Technologies' common stock, approved by stockholders at the April 30, 2026 annual meeting and effectuated via Certificate of Amendment filed August 20, 2026. The reverse split is a governance/capital structure event intended to bring the company into compliance with Nasdaq's minimum bid price requirement. While not a named governance category (exec appointment/departure, auditor change, shareholder vote results), this is clearly a material governance matter affecting all shareholders' holdings and the company's continued listing compliance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-20T12:33:13.842258+00:00","company_name":"bioAffinity Technologies, Inc.","ticker":"BIAFW","filing_date":"2026-08-20"}]}